Survodutide: The Dual GLP-1 / Glucagon Agonist in Phase 3 Research
Survodutide (BI 456906) is the first dual GCGR/GLP-1R agonist to complete Phase 3 evaluation for obesity. The SYNCHRONIZE-1 trial reported 16.6% mean body weight reduction at 76 weeks. This article covers the mechanism, Phase 3 evidence, MASH regulatory designations, and research applications.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
The incretin pharmacology landscape has evolved rapidly from GLP-1 monotherapy to dual and now triple receptor agonism. Survodutide (BI 456906) occupies a distinct position in this progression: a dual glucagon receptor (GCGR) / GLP-1 receptor (GLP-1R) agonist developed by Boehringer Ingelheim and Zealand Pharma that reached Phase 3 evaluation for obesity before any other compound in its mechanistic class. The SYNCHRONIZE program — a suite of Phase 3 trials across obesity and MASH indications — has generated Phase 3 data placing survodutide among the most efficacious investigational anti-obesity compounds in the published literature.
This article summarizes the mechanism of action, the Phase 2 and Phase 3 evidence base, regulatory status, and the research characteristics that distinguish survodutide from other incretin-class compounds.
Research reference only. All information on this page summarizes peer-reviewed scientific literature and is not intended to guide human use. See the Survodutide compound library entry for full pharmacokinetic data and citation index.
What is survodutide?
Survodutide is a 29-amino-acid acylated peptide that functions as a simultaneous agonist at two G-protein coupled receptors: the GLP-1 receptor and the glucagon receptor (GCGR). A C18 fatty acid moiety is attached via a flexible linker to extend plasma half-life and enable once-weekly subcutaneous dosing in human trials. The peptide incorporates a non-coded amino acid (Ac4c) at position 2 for enhanced proteolytic stability, along with C-terminal amidation — structural features shared with other long-acting incretin analogues.
The co-developer, Zealand Pharma, contributed its peptide engineering platform; Boehringer Ingelheim leads clinical development. Survodutide is the first GCGR/GLP-1R dual agonist to complete Phase 3 evaluation for obesity in a controlled trial program.
Mechanism of action
Survodutide's dual receptor mechanism generates two complementary metabolic effects that GLP-1 monotherapy does not produce.
GLP-1 receptor agonism drives appetite suppression through central satiety signaling in the hypothalamus and brainstem, delays gastric emptying, and enhances glucose-dependent insulin secretion from pancreatic beta cells. These effects are well-characterized across the broader GLP-1R agonist class and reduce caloric intake as the primary mechanism of weight reduction.
Glucagon receptor agonism adds a second axis: GCGR activation in hepatocytes increases fatty acid oxidation, reduces hepatic lipid content, and stimulates thermogenesis through mechanisms that increase energy expenditure independently of caloric restriction. This hepatic-thermogenic contribution is mechanistically distinct from anything achievable via GLP-1R alone and provides a specific rationale for the compound's investigation in MASH (metabolic dysfunction-associated steatohepatitis) — a condition where hepatic lipid accumulation and fibrosis drive pathology.
The combination means survodutide addresses the obesity/MASH axis from two directions: reduced caloric intake via GLP-1R and enhanced hepatic fat clearance via GCGR. Investigators studying metabolic phenotypes involving hepatic steatosis, insulin resistance, and visceral adiposity have specific mechanistic reasons to examine this compound class.
Phase 2 evidence
Phase 2 dose-finding data established the efficacy and dose-response profile for survodutide prior to Phase 3 investment. Across 46 weeks in adults with BMI ≥27 kg/m² and obesity-related comorbidities, survodutide produced mean body-weight reductions approximately 5-fold greater than placebo across active dose groups. The 4.8 mg dose arm demonstrated the most robust efficacy signal, establishing this as the Phase 3 dose target.
Phase 2 data also provided initial tolerability characterization. The most common adverse events were gastrointestinal — nausea, vomiting, decreased appetite — consistent with the GLP-1R component. These events were predominantly transient and occurred most frequently during dose escalation.
Phase 3: SYNCHRONIZE-1
The SYNCHRONIZE-1 trial is a multinational, randomized, double-blind, placebo-controlled 76-week study evaluating survodutide as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m² with weight-related comorbidities) without type 2 diabetes. (PMID 41187967, DOI 10.1111/dom.70196)
Headline results from SYNCHRONIZE-1:
- 16.6% mean body weight reduction at 76 weeks versus 3.2% with placebo (p<0.0001), meeting both co-primary endpoints
- 85.1% of survodutide-treated participants achieved ≥5% body weight reduction
- Full efficacy and safety data presented at the ADA 2026 Scientific Sessions
A 16.6% mean weight reduction positions survodutide above what has been reported for approved GLP-1 monotherapy agents (semaglutide 2.4 mg achieved approximately 14.9% in STEP 1) and below what has been reported for the triple agonist retatrutide (approximately 28.7% in TRIUMPH-4). The co-primary endpoint design — which required meeting both a responder threshold and a mean weight-change threshold — reflects the regulatory bar established by prior Phase 3 obesity programs.
MASH indication and regulatory designations
GCGR agonism provides mechanistic justification for investigating survodutide specifically in MASH, where hepatic fat accumulation and progressive fibrosis represent the primary disease burden. The FDA has granted survodutide both Breakthrough Therapy Designation and Fast Track Designation for treatment of non-cirrhotic MASH with stage 2–3 fibrosis, reflecting regulatory recognition that the existing treatment options for this condition are limited and that early clinical data justify expedited development. The EMA additionally granted PRIME designation — its equivalent accelerated pathway for promising medicines.
Phase 3 evaluation of survodutide in MASH is ongoing under the SYNCHRONIZE program. The Phase 2 MASH data published prior to Phase 3 initiation demonstrated meaningful histological improvement (NASH resolution without worsening fibrosis) at a statistically significant rate compared with placebo. Survodutide is therefore one of a small number of investigational compounds with active Phase 3 programs targeting both obesity and MASH simultaneously — a combination that reflects the mechanistic overlap between these two conditions.
Comparison with related compounds
| Feature | Survodutide | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|---|
| Receptor targets | GLP-1R, GCGR | GLP-1R, GIPR | GLP-1R, GIPR, GCGR | GLP-1R |
| Developer | Boehringer Ingelheim / Zealand | Eli Lilly | Eli Lilly | Novo Nordisk |
| Phase 3 obesity result | 16.6% (SYNCHRONIZE-1, 76w) | ~20–22% (SURMOUNT) | 28.7% (TRIUMPH-4) | ~14.9% (STEP 1) |
| MASH-specific development | ✓ Phase 3 ongoing | Phase 2/3 | Phase 3 | Phase 3 |
| FDA regulatory status | Investigational + BTD/FTD for MASH | Approved (obesity + T2D) | Investigational | Approved (obesity + T2D) |
| Dosing frequency | Once-weekly SC | Once-weekly SC | Once-weekly SC | Once-weekly SC |
| Unique mechanistic feature | GCGR-driven hepatic fat oxidation + thermogenesis | GIP/GLP-1 synergy | Triple-agonist GCGR energy expenditure | First-in-class GLP-1R agonist reference |
The key differentiator versus tirzepatide is the receptor substitution: survodutide replaces GIP receptor agonism with glucagon receptor agonism, producing a distinct metabolic profile more focused on hepatic lipid clearance and energy expenditure. The differentiator versus retatrutide is the absence of GIPR agonism, which may affect adipose tissue biology and insulin-secretory pathways in ways researchers are still characterizing across the two compound classes.
Cardiovascular outcomes research
A cardiovascular outcomes trial (CVOT) for survodutide — following the regulatory requirement established after the GLP-1 class expanded — is in the planning or early execution phase. Published SYNCHRONIZE program data do not yet include a primary CVOT, but Phase 2 analyses included cardiometabolic secondary endpoints. Researchers studying the survodutide mechanism's effect on cardiovascular risk markers — including systolic blood pressure, lipid panels, and inflammatory biomarkers — will find relevant secondary endpoint data embedded in the Phase 2 and Phase 3 publications.
Research applications
Survodutide has research utility across several investigational contexts:
Hepatic metabolism and MASH research: The GCGR component makes survodutide one of the few available tools to simultaneously probe GLP-1R-mediated appetite suppression and GCGR-mediated hepatic fat oxidation. Researchers studying the adipose-liver-gut axis find the dual mechanism particularly relevant for dissecting which receptor contribution drives hepatic improvement in steatotic liver disease.
Receptor pharmacology: Comparing survodutide (GLP-1R + GCGR) with tirzepatide (GLP-1R + GIPR) in matched experimental designs allows investigators to isolate the contribution of the GIPR vs. GCGR axis to metabolic outcomes. This comparative design is increasingly used in preclinical metabolic models.
Obesity pharmacology benchmarking: With Phase 3 data now available, SYNCHRONIZE-1 provides a reference weight-loss endpoint (16.6% at 76 weeks) that investigators can use for power calculations in proof-of-concept studies involving other metabolic compounds.
MASH mechanism research: The Breakthrough Therapy Designation signals FDA recognition that the GCGR/GLP-1R mechanism addresses unmet need in MASH. Preclinical and translational researchers studying fibrosis, hepatic stellate cell activation, and NASH histological endpoints may find survodutide an informative probe compound.
Regulatory and compounding status
Survodutide is investigational as of mid-2026. No commercial formulation exists, and no regulatory approval has been granted for any indication. The compound's 503A compounding status is under review as part of the broader FDA review of investigational metabolic peptides. Researchers seeking survodutide for in vitro or animal model work must source it through institutional procurement pathways appropriate for investigational compounds.
Visit the Survodutide compound library entry for full pharmacokinetic parameters, active ClinicalTrials.gov registry entries (NCT identifiers), and the complete citation index.